Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801073 | 0.89 | HTR6 (1.00) | HTR6CYP1A2CYP2D6 | |
| SCHEMBL801394 | 0.87 | HTR6 (0.79) | HTR6CYP1A2CYP2D6 | |
| SCHEMBL801291 | 0.84 | HTR6 (0.60) | HTR6CYP1A2CYP2D6BAZ2BCYP3A4 | |
| SCHEMBL10080982 | 0.81 | HTR6 (0.59) | HTR6 | |
| SCHEMBL6038266 | 0.80 | HTR6 (0.84) | HTR6CYP1A2CYP2D6 | |
| SCHEMBL801289 | 0.77 | HTR6 (0.77) | HTR6CYP1A2CYP2D6BAZ2BLMNA | |
| SCHEMBL801279 | 0.76 | HTR6 (0.72) | HTR6CYP1A2CYP2D6LMNAHTT | |
| SCHEMBL801286 | 0.74 | HTR6 (1.00) | HTR6 | |
| SCHEMBL801088 | 0.74 | HTR6 (0.66) | HTR6CYP1A2CYP2D6LMNAHTT | |
| SCHEMBL25056609 | 0.71 | HTR6 (0.64) | HTR6CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433939-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | Alla Chem, LLC. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2012-03-22 | — | — | US | disclosed |
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2012-03-22 | — | — | US | disclosed |
| WO-2010134846-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | SIGMAR1, ADRA2C, ADRB2 | HTR6 69/4885CYP1A2 648/4885CYP2D6 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.